Changes

Jump to navigation Jump to search

Application of ionising radiation in healthcare

2 bytes added, 18:20, 10 September 2019
Nuclear Medicine
[[file:Bone_Scan_2.jpg|left|200px|thumb|'''Figure 6:''' Example of an abnormal whole-body bone scan. Illustrates an abnormal bone scan in a patient which is marked with arrows. Source: Images Courtesy of Health Sciences Centre - Winnipeg, Manitoba.]]
Nuclear medicine uses radioactive substances, called radiopharmaceuticals, in the diagnosis and treatment of a range of diseases. These substances are chosen or especially developed to be taken up predominantly by one organ or one type of cell in the body. Nuclear medicine offers unique diagnostic information in oncology, cardiology, endocrinology, neurology, nephrology, urology and other areas. Such information is not obtainable, or obtainable only with less accuracy, by other modalities. For nuclear medicine diagnostic procedures, trace amounts of radiopharmaceuticals are administered to patients through injection into veins (intravenous), skin (intradermal) or tissues (intraparenchymal) as well as breathing in (inhalation) or eating/drinking (ingestion). After intake, the function, or physiology, of various tissues, organs or organ systems can be demonstrated. For example, in cancer patients, nuclear medicine imaging can be used for diagnosis (i.e. is a cancer present), staging (i.e. how far has it spread), assessment of response to therapy or of possible disease recurrence. Nuclear medicine cameras are now commonly combined with a CT unit (e.g. hybrid SPECT/CT and PET/CT) which allows precise anatomic localisation of pathology.
[[file:SPECT_CT_gamma.jpg|200px|thumb|'''Figure 7:''' Example of a SPECT/CT gamma camera (Source: © 2018 Siemens Healthcare GmbH. All Rights Reserved. Product photo provided courtesy of Siemens Healthcare GmbH) ]]
Nuclear medicine procedures for treatment are non-invasive and present no risk of direct complications to patients, but limited to several well-established situations where killing hyperfunctioning or malignant cells is important (for example hyperthyroidism, cancer of the thyroid, degenerative and inflammatory diseases of joints, palliative treatment of metastases to the skeleton). In addition, there are many studies showing significant potential for radio-labelled antibodies and receptor-avid peptides to be used in the treatment of several malignancies.

Navigation menu